Acceleració d'operacions SQL en GPU

L'objectiu principal d'aquest projecte és avaluar la tecnologia GPU per determinar si pot ser útil en el sector de les bases de dades. En concret s'utilitza el problema específic de les consultes analítiques amb la finalitat de intentar obtenir un temps de resposta més ràpid. Per aconseguir-ho s'executa el benchmark estàndard TCP-H per poder realitzar la comparació entre tres sistemes de gestió de bases de dades CPU amb un altre implementat per GPU.

Avaluació de l'estàndard SQL : 1999 respecte les característiques orientades a l'objecte que suporta i la seva implementació als SGBD object-relacional

En aquest treball s'intenta fer una síntesi de les especificacions aportades per l'estàndard definit com a SQL: 1999, tot analitzant les ampliacions que fan referència a la nova orientació a l'objecte i a la incorporació de l'herència com a principal element diferenciador.

Avaluació de l'estàndard SQL : 1999 respecte les característiques orientades a l'objecte que suporta i la seva implementació als SGBD object-relational

L'objectiu és estudiar les característiques orientades a l'objecte de l'estàndard SQL: 1999 i posar-les a prova amb un producte comercial que les suporti.

Avaluació de SQL : 1999 respecte les característiques orientades a objectes que suporta i la seva implementació en sistemes de gestió de Bases de Dades

El treball realitzat analitza la manera com l'estàndard SQL:1999 ha incorporat a la seva especificació una sèrie de característiques pròpies de la tecnologia d'orientació a l'objecte. D'aquesta manera, l'estàndard mira de proporcionar als sistemes de gestió de bases de dades algunes de les funcionalitats exigides als sistemes de tercera generació. Aquests sistemes han d'incorporar altres característiques, que estan recollides a l'article Third Generation Database System Manifesto.

SQL-Server 2008 i les noves característiques espacials

La finalitat d'aquest treball és analitzar les noves característiques espacials que ofereix SQLServer 2008. A continuació, com cas pràctic, desenvolupar una aplicació per Windows Mobile on una sèrie de dispositius mòbils puguin indicar la seva ubicació i poder consultar en un mapa, mitjançant el servei en línia Google Maps, la ubicació de la resta de dispositius.

Desarrollo de una interfaz gráfica para la creación de sentencias SQL

Aquest treball tracta sobre la creació d'un projecte de programari lliure, portada a terme des del seu inici fins a la seva conversió, en un projecte que conta amb el suport d'una comunitat d'usuaris. Específicament, la finalitat del projecte de programari lliure generat, és la creació d'una aplicació que sigui capaç de guiar de forma gràfica, ràpida i intuïtiva a l'usuari a través del procés de creació de consultes SQL per a la base de dades postgreSQL.

AlcoNQL : Herramienta de consulta SQL por medio de lenguaje natural

Herramienta de transformación de sentencias en lenguaje natural en consultas SQL, realización de peticiones a la base de datos y muestra de los resultados.

Ultrasound assessment of ocular vascular effects of repeated intravitreal injections of ranibizumab for wet age-related macular degeneration.

PURPOSE: Determine the effect of repeated intravitreal injections of ranibizumab (0.5 mg; 0.05 ml) on retrobulbar blood flow velocities (BFVs) using ultrasound imaging quantification in twenty patients with exudative age-related macular degeneration treated for 6 months. METHODS: Visual acuity (ETDRS), central macular thickness (OCT), peak-systolic, end-diastolic and mean-BFVs in central retinal (CRA), temporal posterior ciliary (TPCA) and ophthalmic (OA) arteries were measured before, 2 days, 3 weeks and 6 months after the first injection. Patients were examined monthly and received 1-5 additional injections depending on ophthalmologic examination results. RESULTS: Six months after the first injection, a significant increase in visual acuity 50.9 ± 25.9 versus 44.4 ± 21.7 (p < 0.01) and decrease in mean central macular thickness 267 ± 74 versus 377 ± 115 μm (p < 0.001) were observed compared to baseline. Although mean-BFVs decreased by 16%±3% in CRA and 20%±5% in TPCA (p < 0.001) 2 days after the first injection, no significant change was seen thereafter. Mean-BFVs in OA decreased by 19%±5% at week 3 (p < 0.001). However, the smallest number of injections (two injections) was associated with the longest time interval between the last injection and month 6 (20 weeks) and with the best return to baseline levels for mean-BFVs in CRA, suggesting that ranibizumab had reversible effects on native retinal vascular supply after its discontinuation. Moreover, a significant correlation between the number of injections and percentage of changes in mean-BFVs in CRA was observed at month 6 (R = 0.74, p < 0.001) unlike TPCA or OA. CONCLUSION: Ranibizumab could impair the native choroidal and retinal vascular networks, but its effect seems reversible after its discontinuation.

Localized interstitial granuloma annulare induced by subcutaneous injections for desensitization.

We describe a patient with interstitial granuloma annulare associated with subcutaneous injection therapy (SIT) for desensitization to a type I allergy. Asymptomatic, erythematous, violaceous annular patches were located at the injection sites on both her arms. Medical history revealed perennial rhinoconjonctivitis treated with SIT (Phostal Stallergen® cat 100% and D. pteronyssinus/D.farinae 50%:50%).

La stratégie thérapeutique anti-VEGF améliore le pronostic visuel de la dégénérescence maculaire liée à l'âge exsudative [Intravitreal anti-VEGF injections improve the visual prognosis of wet age related macular degeneration].

Age related macular degeneration (AMD) is an ocular disease with high prevalence among elderly persons. Two different forms exist: dry AMD, usually slowly progressive, and neovascular AMD (wet form) more aggressive. Photodynamic therapy is used to treat the wet form and anti VEGF treatments recently became available and offer a real change in the prognostic of wet AMD. Two products are registered and used in Switzerland (Macugen and Lucentis), a third "off labels product", Avastin is also currently used in clinical practice. Nevertheless, both the duration of treatment and the number of injection requested to stabilise the disease were not defined in the studies. Ongoing studies are mainly evaluating combined treatments and long acting form of the drug.

Bolus injections of synthetic atrial natriuretic peptide in patients with chronic renal failure or nephrotic syndrome.

The diuretic and natriuretic responses to exogenous synthetic atrial natriuretic peptide (ANP) were evaluated in patients with chronic renal failure (CRF) or nephrotic syndrome (NS). Patients were studied after an oral water load (8 ml/kg in CRF and 20 ml/kg in NS patients). A short intravenous bolus of either a placebo or ANP was administered when urine output was stable. In each group of patients, three doses of ANP were injected at 24 h intervals, i.e., 1.0, 1.5, and 2.0 micrograms/kg in the CRF and 1.0, 1.5, and 3.0 micrograms/kg in the NS group. Blood pressure and heart rate were monitored throughout the study and urinary volume and electrolyte excretion were measured every 20 min up to 3 h after the bolus. An acute and transient fall in blood pressure was observed immediately after the ANP injection. It was more pronounced in CRF than in NS patients. In CRF patients, ANP caused only a slight increase in urinary volume (13.5-44% over baseline) but a significant increase in urinary sodium excretion (45-114% over baseline). In NS patients, significant increases in both urine volume (60-105%) and sodium excretion (149-248%) were also found. In these latter patients, the renal response to ANP appeared to be better preserved. The hemodynamic and renal changes induced by ANP occurred mainly during the first 20 min following the ANP administration, when the peak plasma ANP levels were obtained. However, no clear dose-response effect could be evidenced in either group with the three doses of ANP chosen in this study.

Profiling safety of intravitreal injections for retinoblastoma using an anti-reflux procedure and sterilisation of the needle track.

BACKGROUND: The preservation of globe integrity has always been a major concern during the treatment of retinoblastoma for fear of extraocular or metastatic spread. Intravitreal chemotherapy has been attempted as a desperate salvage therapy only for eyes with refractory retinoblastoma. Published data on the safety and efficacy of this route are, however, limited. METHODS: A modified technique of intravitreal injection in eyes with retinoblastoma is described. All children with retinoblastoma who received one or more intravitreal injections using this technique were retrospectively reviewed concerning ocular complications of the injection procedure as well as clinical or histopathological evidence of tumour spread. RESULTS: 30 eyes of 30 children with retinoblastoma received a total of 135 intravitreal injections, with a median follw-up duration of 13.5 months. No extraocular spread was seen on clinical follow-up in any patients and there was no tumour contamination of the retrieved entry sites histopathologically analysed among the five enucleated eyes. No significant ocular side effects were observed except transient localised vitreous haemorrhage (3/135). CONCLUSION: This technique is potentially safe and effective at a low cost and may play a promising role, especially in the treatment of recurrent and/or resistant vitreous disease in retinoblastoma, as an alternative to enucleation and/or external beam radiotherapy. However, this treatment should not replace the primary standard of care of retinoblastoma and should not be considered in group E eyes. Its application should be approved by an ophthalmological-oncological team and it should be performed by an experienced eye surgeon in a tertiary referral centre after careful selection of a tumour-free injection site.